(Total Views: 749)
Posted On: 09/27/2020 10:15:03 AM
Post# of 154678
Re: invisioner #58108
Invisioner,
Those are very good results. As before, leronlimab either will or will not demonstrate efficacy in CD12.
This heightens the competition IMO. As their report indicates, interim result analysis was pre-planned, which, as CD12 was constructed as an adaptive trial, I expect to see from Cytodyn as well.
Regardless of other therapeutics, if leronlimab does not demonstrate expected efficacy in Covid, it is back to HIV, cancer and the other expected indications.
Those are very good results. As before, leronlimab either will or will not demonstrate efficacy in CD12.
This heightens the competition IMO. As their report indicates, interim result analysis was pre-planned, which, as CD12 was constructed as an adaptive trial, I expect to see from Cytodyn as well.
Regardless of other therapeutics, if leronlimab does not demonstrate expected efficacy in Covid, it is back to HIV, cancer and the other expected indications.
(2)
(0)
